Many HIV-positive persons on HIV medication have trouble taking this medication as prescribed by their doctor (treatment adherence). This threatens the long-term ability of the drugs to preserve a patient’s health. For 1 in 5 in Canada, their medication does not work, in part because of adherence problems. Furthermore, doctors and their HIV-positive patients do not always discuss treatment difficulties and how to resolve them in sufficient depth. The I-Score Study is a 24-month research project that will develop a questionnaire to be filled out by patients as a part of routine HIV care.
Current treatments for pain and inflammation have substantial side effects which limit their use and thus clinical effectiveness. Panag, is a Halifax based drug company which focuses on development of novel therapeutic treatments which can be applied topically to alleviate both pain and inflammation. These compounds are synthetic derivatives of plant-based molecules from the Cannabis sativa plant which have proven to be advantageous in treating pain and inflammation in animal models.
Drug use in older persons is a major public health concern. Even though therapeutic drugs are beneficial for patients’ health in terms of survival or quality of life, patients aged >65 years have a greater risk of developing drug-related complications.
Antibodies are the fastest growing segment of the pharmaceutical market, and with modern engineering technologies antibodies can be programmed to target devastating diseases. Within the immune system, antibodies fight invading bacteria and viruses. High-quality synthetic antibodies directed to disease-related targets have immense therapeutic potential. Development of cell-based assays to enable rapid identification of functionally active antibodies is a critical step in the commercialization process.
In human viral diseases, misbehaviour of the cellular machinery utilizing ubiquitin is frequently observed. Ubiquitin is a small protein that attaches to target proteins in human cells and signals for their destruction. Human deubiquitinases are enzymes that remove ubiquitin to keep protein levels in balance. Viral pathogens have evolved proteins that mimic human deubiquitinases to evade the immune system by interfering with host ubiquitin-dependent processes.
"Parkinsons disease (PD) is a neurodegenerative disorder that affects approximately 1.5% of the global population over age 65. Current therapeutic interventions for PD are typically limited to attempts to correct the depletion of dopamine once motor symptoms become moderate to severe. Interventions with the potential to improve the cognitive function and quality of life of Parkinsons patients by modulating non-motor symptoms, as well as interventions with the potential to slow the rate of loss of dopaminergic neurons and to delay symptom emergence remain an unmet need.
Bones undergo a renewal process by replenishing calcium mineral through a cellular process known as remodeling. Usually, it happens in a balanced manner, but in many bone diseases, the remodeling process is increased with regional bone metabolism. Bisphosphonate (BP) drugs selectivity and strongly bind to bone mineral and become incorporated at active sites of bone turnover in an increased amount.
Natures ability to convert solar energy to chemical energy in photosynthesis has inspired the development of a host of photoredox systems in efforts to mimic this process. The capacity of fluorine atoms to engender a variety of useful properties in pharmaceuticals, agrochemicals, and performance materials has driven significant research efforts toward the invention of novel fluorination reactions. We
proposed to construct C-F bonds by photoreodox catalysis via a radical pathway. Our project will bring potential benefit to academia and industry.
The ability to repair or regenerate damaged heart presents a major challenge in the treatment of cardiovascular diseases. Current treatments are unsuccessful to regenerate dead myocardium and fail to address the challenge caused by the early loss of cardiac cells. The use of a new drug to stimulate protection of the heart during an ongoing myocardial infarct would be very relevant to the clinical setting, to help patients suffering from heart attack.
Cancer cells are known for their unique capacity to survive and grow in a low oxygen tension environment in the middle of a poorly vascularized solid tumor. This adaptation, which is central to the tumorigenesis process, is mediated by precise cellular mechanisms allowing the regulation of gene expression. Thus, the development of small molecules to modulate the activity of transcription factors is of great therapeutic interest. In order to develop such molecules, we plan to finance, with the help of IntelliSyn Pharma and Mitacs, one M.Sc. student.